HomeTestimony

Testimony

  • Congressional Hearing — The Disproportionate Impact of COVID-19 on Communities of Color
    Statement from M. Isabelle Chaudry, Esq. Senior Policy Manager  National Women’s Health Network Hearing on The Disproportionate Impact of COVID-19 on Communities of Color House Ways and Means Committee Even in the early stages of what is likely to be a long pandemic, it’s clear that vulnerable populations (economically, historically and/or ethnic) are disproportionately suffering the impact of COVID-19. In ...
  • FDA Meeting – Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc
    Statement of  M. Isabelle Chaudry Senior Policy Manager National Women’s Health Network  U.S. Food & Drug Administration Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc Thank you for the opportunity to provide oral comments.  My name is M. Isabelle Chaudry and I am here to speak on behalf of the National Women’s Health ...
  • Congressional Hearing – Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety
    Testimony Delivered Before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Hearing “Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety” December 4, 2019 Thank you for the opportunity to testify. My name is M. Isabelle Chaudry and I am the Senior Policy Manager at the National Women’s Health Network, a D.C. ...
  • FDA Meeting – Agile transdermal contraceptive patch AG200-15
    Testimony Delivered at the Meeting of the FDA Bone, Reproductive and Urologic Drugs Advisory Committee October 30, 2019 Thank you for the opportunity to speak on the Agile transdermal contraceptive patch AG200-15. Being able to space, plan, and prevent pregnancy is vital to women’s health. We appreciate the agency’s interest in fostering the development of ...
  • FDA Comments- Makena
    October 28,2019 FDA-2019-N-4203 Bone, Reproductive, and Urological Products Advisory Committee Notice of Meeting, Establishment of Public Docket, Requests for Comments Submitted electronically  To Whom It May Concern: The National Women’s Health Network (NWHN) is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and by choice, we do not accept financial ...
  • FDA Comments – Draft Guidance for Hormonal Contraceptive Products
    September 10, 2019 FDA-2019-D-2153-0002] The Honorable Norman E. Sharpless, M.D. Acting Commissioner of Food and Drugs Food and Drug Administration Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm. 1061  Rockville, MD 20852 Submitted electronically Dear Dr. Sharpless:  Thank you for the opportunity to comment on recently released guidance for safe and effective hormonal contraception. Being able to space, plan, and prevent pregnancy is vital ...
  • FDA Meeting – Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse 
    Testimony Delivered at the Meeting of the FDA Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee February 12, 2019 My name is Cindy Pearson, and I am the executive director of the National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health ...
  • FDA Meeting – Risk Benefit Assessment
    Testimony Delivered at the FDA Public Meeting on Benefit-Risk Assessments in Drug Regulatory Decision-Making September 18, 2017   My name is Caila Brander and I am the Policy Coordinator at The National Women’s Health Network, a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and, ...
  • FDA Meeting – Off-Label Use of Medical Products
    Testimony Delivered at the FDA Public Meeting on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products November 10, 2016 The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and do not accept financial support from ...
  • FDA Comments – Real World Evidence & Essure
    Comments on the Draft Guidance: Use of Real-World Evidence to Support Regulatory Decision Making for Medical Devices   The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and do not accept financial support from insurance companies, drug companies or medical ...
  • FDA Meeting – Clinical Trial Diversity
    Statement of Sarah Christopherson, Program Director National Women’s Health Network February 29, 2016 Food and Drug Administration Safety and Innovation Act 907 Public Meeting: Progress on Enhancing the Collection, Analysis, and Availability of Demographic Subgroup Data   My name is Sarah Christopherson, and I am the Program Director at The National Women’s Health Network, a nonprofit advocacy organization that works ...
  • FDA Scientific Workshop – Labeling of Low-dose Vaginal Estrogen Products
    Statement of Cindy Pearson, Executive Director, National Women’s Health Network Food and Drug Administration Scientific Workshop on Labeling Lower-Dose Estrogen-Alone Products for Symptoms of Vulvar and Vaginal Atrophy My name is Cindy Pearson, and I am the Executive Director of The National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to ...
  • FDA Scientific Workshop – Drug Interactions with Hormonal Contraceptives
    Statement of Christina Cherel, Program Coordinator, National Women’s Health Network Food and Drug Administration Hormal Contraception Public Workshop on Drug Interactions with Hormonal Contraceptives: Public Health and Drug Development Implications My name is Christina Cherel, and I am the Program Coordinator at the National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that ...
  • FDA Meeting – Osteoporosis Drug Development
    Statement of Christina Cherel, Program Coordinator, National Women’s Health Network Food and Drug Administration Meeting of the Division of Bone, Reproductive, and Urologic Products in the Center for Drug Evaluation and Research.  “Osteoporosis Drug Development: Moving Forward” My name is Christina Cherel, and I am the Program Coordinator at The National Women’s Health Network. The National Women’s Health Network ...
  • FDA Meeting – Essure
    Testimony Delivered at the Meeting of the FDA Meeting of the Obstetrics and Gynecology Devices Panel September 24, 2015 My name is Cindy Pearson, and I am the Executive Director of The National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are ...
  • FDA Meeting – Generic Drug Labeling
    Statement of Coco Jervis, J.D., Program Director Food and Drug Administration Public Meeting on Supplemental Applications Propsing Labeling Changes for Approved Drugs and Biological Products March 27, 2015 The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory ...
  • FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder
    Statement of Cindy Pearson, Executive Director, National Women’s Health Network Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder I am speaking on behalf of the National Women’s Health Network, a non-profit advocacy organization that works to improve the health of all women. We are supported by our members, and do not take financial contributions ...
  • FDA Meeting – Lorcaserin
    Statement of Kate Ryan Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Meeting on Lorcaserin The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take ...
  • FDA Meeting – Qnexa Safety and Efficacy
    Statement of Kate Ryan Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee Meeting The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take financial contributions from ...
  • FDA Meeting – Naltrexone/Bupropion (Contrave)
    Statement of Kate Ryan, Program Coordinator Food and Drug Administration (FDA) Gastroenterology Endocrinologic and Metabolic Drugs Advisory Committee The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to the policy and regulatory decisionmaking bodies. We are supported by our members and ...